Shareholder Notice: The Gross Law Firm alerts shareholders who purchased MLTX shares between March 10, 2024, and September 29, 2025, encouraging them to contact the firm for potential lead plaintiff appointment, indicating the company is facing a collective lawsuit.
Allegations of Misleading Statements: The complaint alleges that during the class period, defendants issued materially false and/or misleading statements, failing to disclose that its sole drug candidate SLK shares the same molecular targets as BIMZELX, potentially misleading investors about the company's prospects.
Clinical Benefit Concerns: The lawsuit further claims that SLK's distinct Nanobody structure does not confer a superior clinical benefit over traditional monoclonal antibodies, which could impact investor assessments of its market potential.
Action Deadline: Shareholders must register by December 15, 2025, to participate in the class action, and failure to register in time may affect their rights to claim compensation.
MLTX
$14.32+Infinity%1D
Analyst Views on MLTX
Wall Street analysts forecast MLTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLTX is 15.38 USD with a low forecast of 5.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
Wall Street analysts forecast MLTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLTX is 15.38 USD with a low forecast of 5.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
5 Hold
2 Sell
Moderate Buy
Current: 14.790
Low
5.00
Averages
15.38
High
30.00
Current: 14.790
Low
5.00
Averages
15.38
High
30.00
Cantor Fitzgerald
Prakhar Agrawal
Overweight
maintain
2025-12-04
Reason
Cantor Fitzgerald
Prakhar Agrawal
Price Target
2025-12-04
maintain
Overweight
Reason
STAT reports that the FDA plans to shift toward requiring only one pivotal trial for approval rather than the traditional two, though details and timing remain unclear pending formal agency communication, Cantor Fitzgerald analyst Prakhar Agrawal tells investors in a research note. While the policy could have broad sector implications, it meaningfully boosts the likelihood of MoonLake's sonelokimab securing hidradenitis suppurativa approval based on a single positive pivotal study, the analyst says. Cantor has an Overweight rating on MoonLake shares.
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$30 -> $26
2025-11-21
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$30 -> $26
2025-11-21
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on MoonLake Immunotherapeutics to $26 from $30 and keeps a Buy rating on the shares. The firm cites the Q3 results and completed equity financing for the target drop.
Goldman Sachs
Neutral
maintain
$7 -> $8
2025-11-06
Reason
Goldman Sachs
Price Target
$7 -> $8
2025-11-06
maintain
Neutral
Reason
Goldman Sachs raised the firm's price target on MoonLake Immunotherapeutics to $8 from $7 and keeps a Neutral rating on the shares.
Oppenheimer
Oppenheimer
Outperform
maintain
$25 -> $30
2025-11-06
Reason
Oppenheimer
Oppenheimer
Price Target
$25 -> $30
2025-11-06
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on MoonLake Immunotherapeutics to $30 from $25 and keeps an Outperform rating on the shares. The firm notes MoonLake reported Q3 financials and provided a business update, including results from the Phase 2 LEDA study in palmo-plantar pustulosis, interim adolescent hidradenitis suppurativa data and interim long-term efficacy data from VELA-1/VELA-2.
About MLTX
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
